The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
David H Abramson - One of the best experts on this subject based on the ideXlab platform.
-
intra arterial chemotherapy Ophthalmic Artery chemosurgery for group d retinoblastoma
PLOS ONE, 2016Co-Authors: David H Abramson, Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Anthony B DanielsAbstract:Purpose To report globe salvage rates, patient survival and adverse events of Ophthalmic Artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).
-
carboplatin topotecan Ophthalmic Artery chemosurgery for intraocular retinoblastoma
PLOS ONE, 2013Co-Authors: Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
PloS one, 2013Co-Authors: Jasmine H Francis, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, Y. Pierre Gobin, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive 50 retinal detachment
Pediatric Blood & Cancer, 2012Co-Authors: Sotiria Palioura, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.
Pediatric blood & cancer, 2012Co-Authors: Sotiria Palioura, Ira J Dunkel, Brian P Marr, Scott E Brodie, Y. Pierre Gobin, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
Ira J Dunkel - One of the best experts on this subject based on the ideXlab platform.
-
intra arterial chemotherapy Ophthalmic Artery chemosurgery for group d retinoblastoma
PLOS ONE, 2016Co-Authors: David H Abramson, Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Anthony B DanielsAbstract:Purpose To report globe salvage rates, patient survival and adverse events of Ophthalmic Artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).
-
carboplatin topotecan Ophthalmic Artery chemosurgery for intraocular retinoblastoma
PLOS ONE, 2013Co-Authors: Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
PloS one, 2013Co-Authors: Jasmine H Francis, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, Y. Pierre Gobin, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive 50 retinal detachment
Pediatric Blood & Cancer, 2012Co-Authors: Sotiria Palioura, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.
Pediatric blood & cancer, 2012Co-Authors: Sotiria Palioura, Ira J Dunkel, Brian P Marr, Scott E Brodie, Y. Pierre Gobin, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
Pierre Y Gobin - One of the best experts on this subject based on the ideXlab platform.
-
intra arterial chemotherapy Ophthalmic Artery chemosurgery for group d retinoblastoma
PLOS ONE, 2016Co-Authors: David H Abramson, Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Anthony B DanielsAbstract:Purpose To report globe salvage rates, patient survival and adverse events of Ophthalmic Artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).
-
carboplatin topotecan Ophthalmic Artery chemosurgery for intraocular retinoblastoma
PLOS ONE, 2013Co-Authors: Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive 50 retinal detachment
Pediatric Blood & Cancer, 2012Co-Authors: Sotiria Palioura, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
Scott E Brodie - One of the best experts on this subject based on the ideXlab platform.
-
intra arterial chemotherapy Ophthalmic Artery chemosurgery for group d retinoblastoma
PLOS ONE, 2016Co-Authors: David H Abramson, Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Anthony B DanielsAbstract:Purpose To report globe salvage rates, patient survival and adverse events of Ophthalmic Artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).
-
carboplatin topotecan Ophthalmic Artery chemosurgery for intraocular retinoblastoma
PLOS ONE, 2013Co-Authors: Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
PloS one, 2013Co-Authors: Jasmine H Francis, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, Y. Pierre Gobin, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive 50 retinal detachment
Pediatric Blood & Cancer, 2012Co-Authors: Sotiria Palioura, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.
Pediatric blood & cancer, 2012Co-Authors: Sotiria Palioura, Ira J Dunkel, Brian P Marr, Scott E Brodie, Y. Pierre Gobin, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
Brian P Marr - One of the best experts on this subject based on the ideXlab platform.
-
intra arterial chemotherapy Ophthalmic Artery chemosurgery for group d retinoblastoma
PLOS ONE, 2016Co-Authors: David H Abramson, Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Anthony B DanielsAbstract:Purpose To report globe salvage rates, patient survival and adverse events of Ophthalmic Artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).
-
carboplatin topotecan Ophthalmic Artery chemosurgery for intraocular retinoblastoma
PLOS ONE, 2013Co-Authors: Jasmine H Francis, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
PloS one, 2013Co-Authors: Jasmine H Francis, Ira J Dunkel, Brian P Marr, Scott E Brodie, Gowtham Jonna, Y. Pierre Gobin, David H AbramsonAbstract:Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/− topotecan delivered by Ophthalmic Artery chemosurgery whereby chemotherapy is infused into the eye via the Ophthalmic Artery.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive 50 retinal detachment
Pediatric Blood & Cancer, 2012Co-Authors: Sotiria Palioura, Pierre Y Gobin, Ira J Dunkel, Brian P Marr, Scott E Brodie, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
-
Ophthalmic Artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.
Pediatric blood & cancer, 2012Co-Authors: Sotiria Palioura, Ira J Dunkel, Brian P Marr, Scott E Brodie, Y. Pierre Gobin, David H AbramsonAbstract:Background Superselective delivery of chemotherapy through the Ophthalmic Artery, i.e. Ophthalmic Artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of Ophthalmic Artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received Ophthalmic Artery chemosurgery either as primary treatment or as “salvage” treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of Ophthalmic Artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results A total of 134 Ophthalmic Artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan–Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5–99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25 µV in seven eyes (7/37; 19%), remained stable (change 25 µV in four eyes (4/37; 11%). The Kaplan–Meier retinal reattachment rate was 58% after 3 months and three Ophthalmic Artery chemosurgery infusions (95% confidence interval, 41.9–74.1%). Conclusions Ophthalmic Artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation. Pediatr Blood Cancer 2012; 59: 859–864. © 2012 Wiley Periodicals, Inc.
